Patrick is the managing editor of PharmaBoardroom, writing and editing stories on all things healthcare and the life sciences. The holder of a Master's Degree in International Relations, Patrick has contributed to over 40 country reports and is a fluent Mandarin speaker.
A roundup of the latest news from Spanish pharma, including Almirall’s licensing deal with EpimAb Biotherapeutics; the opening of Insud Pharma’s oligonucleotides centre in India, and Esteve Química’s new FDA-cleared…
Indian pharma companies have been building a broader presence in LatAm markets over the past two decades. With well-established trade relations already in place, the region offers a series of unique…
LEO Pharma has been in the midst of a shakeup since the beginning of 2022. After naming a new CEO and announcing a major restructuring, the Danish dermatology pharma has…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
Morocco is undergoing ambitious reforms, extending universal healthcare coverage to all its citizens while resolving the shortcomings laid bare during the COVID-19 pandemic. Endorsed by a USD 450 million Program-for-Results…
While much of PharmaBoardroom’s recent report on Hong Kong and the Greater Bay Area looks at how Hong Kong is attempting to position itself as a development and financing hub…
Globally, while there is broad stakeholder alignment on topics like clinical trials and innovation, there is real divergence in approaches to pharmacoeconomics and health technology assessment (HTA). This is perhaps…
Could the UK’s re-joining of Horizon Europe, the EU’s EUR 95 billion research funding programme, be the latest sign that the country is ready to win back its global scientific…
A roundup of some of the latest pharma news from China including Pfizer’s first Asia launch of Rimegepant migraine treatment in Hong Kong; Zhifei and GSK’s shingles vaccine deal, and…
The speed with which Pfizer-BioNTech and Moderna’s COVID-19 vaccines were brought forward may have made the mRNA technology behind them appear novel. In fact, the pioneers whose discoveries enabled the…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
See our Cookie Privacy Policy Here
